For patients undergoing percutaneous coronary intervention (PCI), tailoring antiplatelet therapy based on the results of platelet function testing makes no difference in the risk of recurrent ischemic ...
In patients undergoing percutaneous coronary intervention (PCI), intensifying antiplatelet therapy based on platelet reactivity testing reduces cardiovascular mortality and stent thrombosis, according ...
Use of platelet function testing during dual antiplatelet therapy, including a P2Y12 antagonist, in acute coronary syndromes does not improve clinical outcomes. Researchers at King's College London ...
November 10, 2011 (San Francisco, California)— Investigators who explored platelet-function testing for guiding antiplatelet therapy in a low-risk PCI population, who earlier this year had announced ...
Aortic-valve stenosis can be complicated by bleeding that is associated with acquired type 2A von Willebrand syndrome. However, the prevalence and cause of the hemostatic abnormality in aortic ...
HOUSTON--(BUSINESS WIRE)--Houston-based Aggredyne, Inc., a biomedical diagnostics company widely recognized as a leader in the field of platelet function testing, has appointed Dr. Jeffrey Dahlen as ...
Today at the American Association of Clinical Chemistry (AACC) Annual Meeting in Chicago, Illinois, Dade Behring Inc. (NASDAQ:DADE) introduced the BCS(R) XP System, the newest addition to the ...
The global platelet function test market is projected to be valued at USD 1.38 billion in 2025 and is expected to reach USD 2.61 billion by 2035, registering a CAGR of 6.3% during the forecast period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback